Objective: To evaluate MR accuracy for staging endometrial carcinoma with different FIGO staging systems.
Methods: Between August 2006 and July 2010, 95 women underwent surgery for endometrial carcinoma.In each patient, endometrial carcinoma was staged with magnetic resonance (MR) findings based on the old FIGO staging system and then repeated according to the new FIGO staging system for comparisons.Histopathologic findings were used as a golden standard to compare the sensitivity, specificity, accuracy, positive predictive value and negative predictive value.
Results: The accuracy of MRI in the staging of endometrial carcinoma stageI, II and III with the old FIGO staging system were 83.2%, 86.3% and 92.6% versus 88.4%, 96.8% and 91.6% respectively with the new FIGO staging criteria.According the old FIGO staging system, the sensitivity of stage IA, IB and IC were 51.8%, 76.5% and 50.0% and the specificity 85.3% , 55.7% and 95.4% respectively; the sensitivity of stage IIA and IIB were merely 12.5% and 20.0% and the specificity 97.7% and 100.0%.With the new FIGO staging criteria, the above indices were 97.1%, 55.6%, 57.7%, 95.3%, 40.0% and 100.0% respectively.
Conclusion: With new FIGO staging system versus the old one, the accuracy of MR imaging in the preoperative staging of endometrial carcinoma increases.
Download full-text PDF |
Source |
---|
Cancers (Basel)
February 2025
Department of Clinical Pathomorphology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 85-094 Bydgoszcz, Poland.
Endometrial cancer (EC) is a heterogeneous gynecological malignancy characterized by varied clinical outcomes and complex molecular mechanisms. The dysregulation of cyclin K (CCNK), a key regulator of transcription and cell cycle progression, has been implicated in cancer development. This study aimed to investigate CCNK expression at the protein level in EC tissues and at the mRNA level using in silico analysis.
View Article and Find Full Text PDFCancers (Basel)
February 2025
Department of Pathology, Medical University of Vienna, 1090 Vienna, Austria.
Background/objectives: The surgeon's subjective intraoperative evaluation is the standard of care to assess postoperative residual disease (RD) in advanced epithelial ovarian cancer (EOC). We investigated the feasibility of ctDNA as an objective marker for postoperative RD.
Methods: This prospective study included 27 patients with advanced ovarian cancer (FIGO IIIA1-IVB) who underwent primary surgery between July 2021 and July 2022.
Int J Gen Med
March 2025
Medical Imaging Center, Xi'an People's Hospital (Xi'an Fourth Hospital), Xi'an, Shaanxi Province, People's Republic of China.
Background: Cervical cancer remains a major cause of mortality among women globally, with lymph node metastasis (LNM) being a critical determinant of patient prognosis.
Methods: In this study, MRI scans from 153 cervical cancer patients between January 2018 and January 2024 were analyzed. The patients were assigned to two groups: 103 in the training cohort; 49 in the validation cohort.
Cancer Med
March 2025
Department of Gynecology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Backgrounds: A growing number of systematic bioinformatics analyses were conducted to investigate the mechanism of interaction between long non-coding RNA (lncRNA) and endometrial carcinoma (EC) to predict the prognosis. However, there is no evidence-based evidence that abnormal lncRNA expression is strongly associated with the pathological characteristics and prognosis of EC patients. In this meta-analysis, we systematically evaluated the relationship between upregulated lncRNA expression levels and clinicopathological features, five-year survival rate, and progression-free survival (PFS).
View Article and Find Full Text PDFAm J Surg Pathol
March 2025
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School.
Endometrial gastric (gastrointestinal)-type mucinous adenocarcinoma (EmGA) is rare and was introduced as a new entity in the latest World Health Organization (WHO) classification of female genital tumors. Herein, we report a detailed clinicopathologic, immunohistochemical, and molecular study of 27 EmGA, the largest published series to date. The cohort consisted of 27 patients (median age 69 y; range 42 to 87 years).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!